Frovatriptan

A long-acting triptan (serotonin 5-HT1B/1D agonist), FDA-approved for acute treatment of migraine with or without aura in adults.

psilodex.org/m/frovatriptan · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~26 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Frovatriptan”, v2026.10.05. psilodex.org/m/frovatriptan

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Generic only in US

FDA-approved for

Migraine attacks (acute treatment)

Sources [1]

Other safety

Contraindicated in coronary artery disease or coronary vasospasm, Wolff-Parkinson-White syndrome, stroke or TIA history, hemiplegic or basilar migraine, peripheral vascular disease, uncontrolled hypertension, and within 24 hours of another triptan or an ergot-type drug.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

It may add to psilocybin's serotonin effects and blood pressure rise (not studied with psilocybin); a dose from the day before may linger.

Detail Frovatriptan may add to psilocybin's serotonin-boosting effects and brief blood pressure rise; there are no psilocybin data. With a half-life of about 26 hours, a dose taken the day before may still be present. It is a long-acting triptan (5-HT1B/1D agonist) that narrows blood vessels. Its label reports serotonin syndrome with SSRIs, SNRIs, TCAs and MAO inhibitors. Its label also reports rare significant blood pressure elevation, including hypertensive crisis (a dangerous spike). Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~26 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

FROVATRIPTAN (frovatriptan succinate) tablet, film coated (Amneal) · FDA label (DailyMed) — revised 2026-03 | Serotonergic: 5.7 Serotonin Syndrome "Serotonin syndrome may occur with frovatriptan succinate, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors" | Raises blood pressure or heart rate: 5.8 Increase in Blood Pressure "Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists" | 12.3 Pharmacokinetics "The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →